Literature DB >> 8145037

A human tumor necrosis factor (TNF) alpha mutant that binds exclusively to the p55 TNF receptor produces toxicity in the baboon.

K J Van Zee1, S A Stackpole, W J Montegut, M A Rogy, S E Calvano, K C Hsu, M Chao, C L Meschter, H Loetscher, D Stüber.   

Abstract

A number of recent studies have demonstrated that cellular responses to tumor necrosis factor (TNF) mediated by the p55 and the p75 TNF receptors are distinct. To evaluate the relative in vivo toxicities of wild-type TNF alpha (wtTNF alpha) and a novel p55 TNF selective receptor agonist, healthy, anesthetized baboons (Papio sp.) were infused with a near-lethal dose of either wtTNF alpha or a TNF alpha double mutant (dmTNF alpha) that binds specifically to the p55, but not to the p75, TNF receptor. Both wtTNF alpha and dmTNF alpha produced comparable acute hypotension, tachycardia, increased plasma lactate, and organ dysfunction in Papio. However, administration of wtTNF alpha produced a marked granulocytosis and loss of granulocyte TNF receptors, whereas little if any changes in neutrophil number or cell surface TNF receptor density were seen after dmTNF alpha mutant administration. Infusion of dmTNF alpha resulted in a plasma endogenous TNF alpha response that peaked after 90-120 min. We conclude that selective p55 TNF receptor activation is associated with early hemodynamic changes and the autocrine release of endogenous TNF alpha. Significant systemic toxicity results from p55 TNF receptor activation, but the role of the p75 TNF receptor in systemic TNF toxicity requires further study.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8145037      PMCID: PMC2191464          DOI: 10.1084/jem.179.4.1185

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  23 in total

1.  Effects of intravenous IL-8 administration in nonhuman primates.

Authors:  K J Van Zee; E Fischer; A S Hawes; C A Hébert; T G Terrell; J B Baker; S F Lowry; L L Moldawer
Journal:  J Immunol       Date:  1992-03-15       Impact factor: 5.422

Review 2.  Clinical studies with TNF.

Authors:  T Taguchi; Y Sohmura
Journal:  Biotherapy       Date:  1991

Review 3.  The pathophysiology of tumor necrosis factors.

Authors:  P Vassalli
Journal:  Annu Rev Immunol       Date:  1992       Impact factor: 28.527

4.  High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.

Authors:  D Lienard; P Ewalenko; J J Delmotte; N Renard; F J Lejeune
Journal:  J Clin Oncol       Date:  1992-01       Impact factor: 44.544

5.  Purification and partial amino acid sequence analysis of two distinct tumor necrosis factor receptors from HL60 cells.

Authors:  H Loetscher; E J Schlaeger; H W Lahm; Y C Pan; W Lesslauer; M Brockhaus
Journal:  J Biol Chem       Date:  1990-11-25       Impact factor: 5.157

6.  Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin.

Authors:  A Ashkenazi; S A Marsters; D J Capon; S M Chamow; I S Figari; D Pennica; D V Goeddel; M A Palladino; D H Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

7.  The two different receptors for tumor necrosis factor mediate distinct cellular responses.

Authors:  L A Tartaglia; R F Weber; I S Figari; C Reynolds; M A Palladino; D V Goeddel
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-15       Impact factor: 11.205

8.  Recombinant 55-kDa tumor necrosis factor (TNF) receptor. Stoichiometry of binding to TNF alpha and TNF beta and inhibition of TNF activity.

Authors:  H Loetscher; R Gentz; M Zulauf; A Lustig; H Tabuchi; E J Schlaeger; M Brockhaus; H Gallati; M Manneberg; W Lesslauer
Journal:  J Biol Chem       Date:  1991-09-25       Impact factor: 5.157

9.  Species specificity and involvement of other cytokines in endotoxic shock action of recombinant tumour necrosis factor in mice.

Authors:  P G Brouckaert; B Everaerdt; C Libert; N Takahashi; W Fiers
Journal:  Agents Actions       Date:  1989-01

10.  Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo.

Authors:  K J Van Zee; T Kohno; E Fischer; C S Rock; L L Moldawer; S F Lowry
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

View more
  13 in total

1.  Renal-Specific Silencing of TNF (Tumor Necrosis Factor) Unmasks Salt-Dependent Increases in Blood Pressure via an NKCC2A (Na+-K+-2Cl- Cotransporter Isoform A)-Dependent Mechanism.

Authors:  Shoujin Hao; Mary Hao; Nicholas R Ferreri
Journal:  Hypertension       Date:  2018-05-07       Impact factor: 10.190

Review 2.  Role of renal transporters and novel regulatory interactions in the TAL that control blood pressure.

Authors:  Lesley A Graham; Anna F Dominiczak; Nicholas R Ferreri
Journal:  Physiol Genomics       Date:  2017-04-07       Impact factor: 3.107

3.  Generation of a mouse tumor necrosis factor mutant with antiperitonitis and desensitization activities comparable to those of the wild type but with reduced systemic toxicity.

Authors:  R Lucas; B Echtenacher; E Sablon; P Juillard; S Magez; J Lou; Y Donati; F Bosman; A Van de Voorde; L Fransen; D N Männel; G E Grau; P de Baetselier
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

4.  Safety evaluation and pharmacokinetics of a novel human tumor necrosis factor-alpha exhibited a higher antitumor activity and a lower systemic toxicity.

Authors:  Meng Li; Xin Qin; Xiaochang Xue; Cun Zhang; Zhen Yan; Wei Han; Chris Komarck; Thomas D Wang; Yingqi Zhang
Journal:  Anticancer Drugs       Date:  2010-03       Impact factor: 2.248

Review 5.  TNFR2 antagonist and agonist: a potential therapeutics in cancer immunotherapy.

Authors:  Sameer Quazi
Journal:  Med Oncol       Date:  2022-09-29       Impact factor: 3.738

6.  Molecular and functional evidence for in vitro cytokine enhancement of human and murine target cell sensitivity to glucocorticoids. TNF-alpha priming increases glucocorticoid inhibition of TNF-alpha-induced cytotoxicity/apoptosis.

Authors:  M Costas; T Trapp; M P Pereda; J Sauer; R Rupprecht; V E Nahmod; J M Reul; F Holsboer; E Arzt
Journal:  J Clin Invest       Date:  1996-09-15       Impact factor: 14.808

7.  Immunological markers of childhood fevers in an area of intense and perennial malaria transmission.

Authors:  N Hurt; M Thein; T Smith; G Bordmann; H Gallati; N Drees; M Tanner; N Weiss
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

8.  The expression of tumor necrosis factor-alpha (TNF-alpha) by the intrathecal injection of lipopolysaccharide in the rat spinal cord.

Authors:  Aiguo Shen; Dan Zhou; Qin Shen; Hai-ou Liu; Linlin Sun; Yonghua Liu; Jianping Chen; Junling Yang; Yuhong Ji; Chun Cheng
Journal:  Neurochem Res       Date:  2008-07-10       Impact factor: 3.996

Review 9.  Cytokines and the early vein graft: strategies to enhance durability.

Authors:  C Keith Ozaki
Journal:  J Vasc Surg       Date:  2007-06       Impact factor: 4.268

10.  Lipopolysaccharide-induced upregulation of tumor necrosis factor-alpha (TNF-alpha) and TNF receptors in rat sciatic nerve.

Authors:  Youhua Wang; Dan Zhou; Qin Shen; Chun Cheng; Hai-ou Liu; Yongwei Qin; Linlin Sun; Feng Xiao; Jian Zhao; Aiguo Shen
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 2.866

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.